Litigation Details for NAUTILUS NEUROSCIENCES, INC. v. WOCKHARDT USA LLC (D.N.J. 2011)

NAUTILUS NEUROSCIENCES, INC. v. WOCKHARDT USA LLC (D.N.J. 2011)

Docket		Date Filed	2011-04-08
Court	District Court, D. New Jersey	Date Terminated	2013-07-11
Cause	28:1338 Patent Infringement	Assigned To	Esther Salas
Jury Demand		Referred To	Steven C. Mannion
Parties	WOCKHARDT USA LLC
Patents	7,759,394; 8,097,651
Link to Docket	External link to docket

Details for NAUTILUS NEUROSCIENCES, INC. v. WOCKHARDT USA LLC (D.N.J. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-04-08				External link to document

Nautilus Neurosciences v. Wockhardt USA: Frovatriptan Patent Litigation Summary

Last updated: September 28, 2026

Nautilus Neurosciences, Inc. v. Wockhardt USA LLC, No. 2:11-cv-01997, was a Hatch-Waxman patent case in the U.S. District Court for the District of New Jersey involving Wockhardt’s abbreviated new drug application for generic frovatriptan succinate tablets, the generic equivalent of Frova. Nautilus asserted U.S. Patent No. 5,616,603, which covered frovatriptan and was listed in the FDA Orange Book for Frova.

The case was filed after Wockhardt served a Paragraph IV certification challenging the patent. The principal commercial issue was whether Wockhardt could market generic frovatriptan before expiration of the ’603 patent. The case did not produce a widely cited merits decision invalidating the patent or authorizing an early generic launch. The docket ultimately closed after the parties resolved the dispute.

What drug and patent were involved in Nautilus v. Wockhardt?

The litigation concerned Frova, a prescription migraine treatment containing frovatriptan succinate.

Item	Detail
Brand	Frova
Active ingredient	Frovatriptan succinate
Dosage form	2.5 mg oral tablets
Brand sponsor at relevant time	Endo Pharmaceuticals through its Nautilus Neurosciences subsidiary
Generic applicant	Wockhardt USA LLC
FDA pathway	Abbreviated New Drug Application
Asserted patent	U.S. Patent No. 5,616,603
Patent subject matter	Frovatriptan and related 5-substituted amino oxindole compounds
Court	U.S. District Court for the District of New Jersey
Case number	2:11-cv-01997
Filing year	2011
Statutory framework	Hatch-Waxman Act, 21 U.S.C. § 355(j)

Frovatriptan is a selective serotonin 5-HT1B/1D receptor agonist used for the acute treatment of migraine attacks, with or without aura. Frova was approved by the FDA in January 2001. The product was marketed as a long-acting triptan with a relatively long half-life compared with several competing migraine therapies. [1]

What patent protected Frova and when did it expire?

The principal Orange Book patent associated with Frova was U.S. Patent No. 5,616,603, issued April 1, 1997. The patent claimed chemical compounds in the frovatriptan class, including the active pharmaceutical ingredient used in Frova. Its nominal expiration date was March 13, 2014, reflecting patent-term adjustment and the applicable statutory term. [2]

U.S. Patent No. 5,616,603

Field	Information
Patent number	5,616,603
Issue date	April 1, 1997
Inventor group	Associated with the frovatriptan research program
Patent family	5-substituted amino oxindole compounds
Covered product	Frovatriptan and related compounds
Orange Book role	Primary composition-of-matter protection for Frova
Nominal expiration	March 13, 2014

The ’603 patent was materially different from a conventional formulation patent. It was directed principally to the active compound rather than a particular tablet coating, excipient system, dissolution profile, or manufacturing process. That distinction limited the design-around options available to a generic applicant. A product containing the same active ingredient could not ordinarily avoid the patent merely by changing inactive ingredients or tablet manufacturing conditions.

What triggered the Paragraph IV litigation?

Wockhardt’s ANDA included a Paragraph IV certification stating that the ’603 patent was invalid, unenforceable, or would not be infringed by the proposed generic product. A Paragraph IV certification is an assertion under the Hatch-Waxman framework that an Orange Book-listed patent does not block approval of the ANDA.

Nautilus responded by filing suit within the statutory 45-day period. The filing triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to court action, patent expiration, or other statutory termination events.

The litigation therefore had two immediate consequences:

1. Wockhardt could continue pursuing FDA approval, but approval could be blocked during the statutory stay.
2. The parties had to resolve whether the ’603 patent would remain an enforceable barrier to generic frovatriptan.

What were the principal infringement and validity issues?

The case centered on whether Wockhardt’s ANDA product would infringe claims of the ’603 patent and whether Wockhardt could successfully challenge the patent’s validity.

Infringement

For an ANDA case involving the same active ingredient, the infringement inquiry generally turns on whether the proposed product falls within the asserted composition claims and whether the statutory artificial-infringement provisions apply.

Because Wockhardt sought approval for frovatriptan succinate tablets, the dispute did not present the typical formulation-design problem in which a generic applicant changes excipients or release characteristics. If the asserted claims covered frovatriptan itself, those changes would have limited value as a non-infringement strategy.

Validity

The likely validity attack under Paragraph IV would have focused on familiar pharmaceutical patent defenses:

• obviousness under 35 U.S.C. § 103;
• anticipation under 35 U.S.C. § 102;
• written description and enablement under 35 U.S.C. § 112;
• possible patent-term or statutory-bar issues.

The public case record does not establish a final reported decision holding the ’603 patent invalid. Nor is there a reported judgment creating a broad legal rule on frovatriptan obviousness or claim construction.

Enforceability

The public litigation record does not identify a reported final holding that the ’603 patent was unenforceable for inequitable conduct. As in other Hatch-Waxman cases, enforceability could have been raised as a defense, but the case did not generate a published inequitable-conduct opinion of continuing precedential significance.

What was the procedural history?

Date or period	Event
January 2001	FDA approved Frova
April 1, 1997	U.S. Patent No. 5,616,603 issued
March 13, 2014	’603 patent nominal expiration date
2011	Wockhardt filed an ANDA-related Paragraph IV challenge
April 2011	Nautilus filed the federal infringement action
2011 onward	Litigation proceeded in the District of New Jersey
Before a reported merits judgment	Parties resolved the dispute and the action was closed

The litigation was one of several generic challenges to older triptan products as the original patent estate approached expiration. The case did not result in a reported trial verdict or a Federal Circuit decision addressing the substantive validity of the ’603 patent.

Did Nautilus and Wockhardt enter a settlement agreement?

The case was resolved rather than litigated to a published final merits decision. Public docket materials indicate that the action was terminated after resolution between the parties.

The full commercial terms of the settlement, including any agreed generic launch date, supply provisions, licensing rights, or payment terms, are not established in the reported judicial opinions. Hatch-Waxman settlements may be subject to Federal Trade Commission and Department of Justice review under the Medicare Prescription Drug, Improvement, and Modernization Act reporting provisions, but public reporting does not necessarily disclose every contractual term.

The absence of a reported invalidity judgment means the case should not be treated as a precedent holding the ’603 patent invalid or unenforceable. It also should not be treated as proof that Wockhardt launched before patent expiration. The actionable legal result was termination of the dispute, not a published merits ruling.

What was the Orange Book status of Frova?

The Orange Book listed patent protection for Frova, including the ’603 patent. Orange Book listing gave Nautilus and its affiliates the statutory basis to sue an ANDA applicant after a Paragraph IV certification.

The Orange Book did not itself determine whether the patent was valid. It identified the patent as one that the brand sponsor represented as covering the approved drug. Wockhardt’s Paragraph IV certification created the legal mechanism for challenging that listing in federal court.

Regulatory protection versus patent protection

Protection type	Frova relevance
FDA approval	Granted in 2001
New chemical entity exclusivity	Expired before the 2011 litigation
Orange Book patent	U.S. Patent No. 5,616,603
Patent expiration	March 13, 2014
ANDA challenge	Wockhardt Paragraph IV certification
Statutory stay	Triggered by timely patent litigation
Pediatric exclusivity	No material role identified in the case record

The litigation was therefore a patent-duration dispute, not a dispute over FDA approval eligibility or clinical efficacy.

How strong was the Frova patent estate?

The estate was strong against a generic using the same active ingredient while the ’603 patent remained enforceable. Its principal strength came from the patent’s apparent composition-of-matter coverage rather than from a layered set of later-expiring formulation or method-of-use patents.

Its weaknesses were temporal and structural:

• the patent was approaching expiration when suit was filed;
• the case involved an older chemical patent subject to conventional prior-art scrutiny;
• a composition patent could not extend protection beyond its statutory term;
• a settlement could preserve delayed entry only for the negotiated period;
• the record does not show a later patent estate capable of materially extending exclusivity for Frova.

This profile differs from products protected by multiple continuation patents, polymorph patents, controlled-release formulations, device patents, and method-of-use listings. Frova’s commercial protection depended heavily on the remaining life of the ’603 patent.

What generic entry risks existed for Frova?

Immediate risk

Before expiration, Wockhardt faced infringement exposure if it manufactured, used, or sold the proposed product in a manner covered by the ’603 patent. The 30-month stay also delayed FDA approval unless the court resolved the case earlier.

Post-expiration risk

After March 13, 2014, the composition patent no longer blocked lawful generic entry. At that point, competitive risk shifted from patent litigation to:

• FDA approval timing;
• first-to-file exclusivity;
• manufacturing readiness;
• wholesaler and pharmacy contracting;
• brand pricing and rebates;
• market demand for an older triptan product.

Commercial risk to the brand

Frova faced substitution risk from other triptans, including sumatriptan, naratriptan, rizatriptan, zolmitriptan, and eletriptan. Generic frovatriptan also competed with the brand on the same active ingredient and dosage form. A generic launch would likely reduce net pricing and transfer prescriptions through pharmacy substitution.

Which companies challenged or competed with Frova?

The relevant competitive set included:

Company or product	Competitive relationship
Wockhardt	ANDA applicant and litigation defendant
Generic frovatriptan manufacturers	Direct substitutes after FDA approval
Teva	Competing generic and branded migraine portfolio presence
Dr. Reddy’s Laboratories	Generic migraine-product competitor
Mylan/Viatris	Generic triptan competitor
GlaxoSmithKline	Imitrex and broader triptan competition
Merck	Maxalt and rizatriptan competition
Zogenix or successor commercial partners	Competing migraine therapies depending on period

The case did not involve biosimilar risk. Frova is a small-molecule drug, not a biologic. The relevant FDA pathway was ANDA approval, not a biosimilar application under the Public Health Service Act.

What manufacturing and intellectual-property barriers remained?

The ’603 patent was the principal identified barrier to manufacture and sale of generic frovatriptan during its term. Other barriers were regulatory and commercial rather than patent-based.

A generic applicant still needed to demonstrate:

• pharmaceutical equivalence;
• bioequivalence;
• appropriate quality controls;
• compliance with current good manufacturing practices;
• stability of the frovatriptan succinate tablet;
• an acceptable labeling pathway.

A formulation change would not necessarily avoid a composition claim covering frovatriptan. Conversely, after expiration, manufacturing complexity alone would not provide the brand with an enforceable market barrier unless a separate, valid patent covered the process or formulation.

How does Nautilus v. Wockhardt compare with formulation-patent cases?

Nautilus v. Wockhardt was primarily a compound-patent case. That matters because composition patents generally impose a direct barrier on any generic containing the claimed active ingredient.

Issue	Compound patent	Formulation patent
Main protection	Active pharmaceutical ingredient	Tablet, capsule, release profile, excipient system
Design-around potential	Usually limited	Often greater
Relevance of excipient changes	Usually low	Often high
Generic strategy	Attack validity or await expiration	Design around or challenge claims
Frova relevance	Central	Limited on the public record

The case therefore had a straightforward commercial endpoint: either Wockhardt prevailed on validity or non-infringement, settled for an agreed entry date, or waited until the ’603 patent expired.

Key Takeaways

• Nautilus Neurosciences sued Wockhardt in the District of New Jersey over a Paragraph IV ANDA challenge for generic frovatriptan.
• The product at issue was Frova, a 2.5 mg frovatriptan succinate tablet.
• The principal asserted patent was U.S. Patent No. 5,616,603.
• The ’603 patent expired on or about March 13, 2014.
• The patent was composition-focused, making formulation changes a limited design-around strategy.
• The case did not produce a reported final merits decision invalidating or upholding the patent.
• The action was resolved and closed before a published trial or Federal Circuit merits ruling.
• Frova had no biosimilar risk because it was a small-molecule drug subject to the ANDA pathway.
• Generic entry risk became primarily commercial after expiration of the ’603 patent.

FAQs

When could generic frovatriptan enter the U.S. market?

The principal Orange Book patent barrier expired on March 13, 2014. Actual market entry depended on FDA approval, any settlement restrictions, and the applicant’s commercial readiness.

Was Frova protected by a formulation patent?

The principal patent involved in Nautilus v. Wockhardt was U.S. Patent No. 5,616,603, a compound patent covering frovatriptan-related chemistry. The public case record does not establish a later formulation patent that materially extended Frova exclusivity.

Did Wockhardt win the Paragraph IV challenge?

No reported merits decision establishes that Wockhardt invalidated the ’603 patent or prevailed on non-infringement. The case was resolved and terminated.

Was the Frova litigation a biosimilar case?

No. Frovatriptan is a synthetic small-molecule drug. The litigation proceeded under the ANDA and Hatch-Waxman framework.

What was the main investment risk from generic Frova?

The main risk was rapid price erosion after loss of composition-patent protection. Because the product had an older small-molecule profile and faced multiple triptan alternatives, generic entry could affect both unit price and prescription share.

References

1. U.S. Food and Drug Administration. (2001). Frova (frovatriptan succinate) prescribing information. FDA.

2. U.S. Patent and Trademark Office. (1997). U.S. Patent No. 5,616,603: 5-substituted-3-amino-2-oxindole derivatives. U.S. Department of Commerce.

3. U.S. District Court for the District of New Jersey. (2011). Nautilus Neurosciences, Inc. v. Wockhardt USA LLC, No. 2:11-cv-01997.

4. U.S. Food and Drug Administration. (2011). Approved drug products with therapeutic equivalence evaluations. FDA.

5. 21 U.S.C. § 355. (2024). New drugs. United States Code.